| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. | Lancet | 2011 | 2.34 |
| 2 | Physical activity and inactivity patterns in India - results from the ICMR-INDIAB study (Phase-1) [ICMR-INDIAB-5]. | Int J Behav Nutr Phys Act | 2014 | 1.35 |
| 3 | Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes. | Obstet Gynecol | 2013 | 0.85 |
| 4 | Cluster analysis and phylogenetic relationship in biomarker identification of type 2 diabetes and nephropathy. | Int J Diabetes Dev Ctries | 2010 | 0.82 |
| 5 | Importance of achieving the composite endpoints in diabetes. | Indian J Endocrinol Metab | 2013 | 0.81 |